Relapsed intravascular large B-cell lymphoma
نویسندگان
چکیده
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. A 44-year-old woman presented with myalgia and fever. Initial laboratory results were: White blood cell (WBC) count, 7.8×10 9 /L; hemoglobin, 11.3 g/dL; platelet count, 42×10 9 /L; and lactate dehydrogenase, 619 IU/L. Peripheral blood cell morphology showed leukoerythroblastic features (nRBC, 8/100 WBCs). Abdominal computed tomography (CT) indicated hepatosplenomegaly. Bone marrow biopsy showed focal large cell aggregates with prominent nucleoli in capillaries (A, H&E stain, ×400; B, CD20 stain, ×400). These cells were positive for CD5 and CD20 and negative She was diagnosed with intravascular large B-cell lymphoma and treated with rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone (R-CHOP) combination chemotherapy. Three months after auto-peripheral blood stem cell transplantation, she was readmitted due to coughing, sputum, and myalgia. Bone marrow analysis showed an intravascular large B-cell lymphoma recurrence with normal karyotype (D, Wright-Giemsa stain, ×1,000). In a BCL6 dual-color, break-apart probe (Vysis/Abbott Molecular, Des Plaines, IL, USA) initial diagnostic specimen FISH study, 9.8% (49/500) of the cells had a 2-green 1-fusion abnormal signal pattern, suggesting 3q27 rearrangement, while no abnormal signal patterns were observed, although abnormal lymphoid cells comprised 6.8% of the bone marrow at relapse.
منابع مشابه
Intravascular Large B-cell Lymphoma: A Report of Two Cases
One of the rare variants of extranodal large B-cell lymphoma is intravascular large B-cell lymphoma (IVLBCL). Characteristics of IVLBCL include intraluminal selective proliferation of atypical lymphoid cells in small to medium-sized vessels. The etiologic of IVLBCL is unknown, but due to the growth pattern of this tumor, it is speculated that IVLBCL is caused by a defect in homing receptor of t...
متن کاملEarly detection of intravascular large B-cell lymphoma by 18FDG-PET/CT with diffuse FDG uptake in the lung without respiratory symptoms or chest CT abnormalities
Intravascular large B-cell lymphoma (IVLBCL) is a rare and aggressive subtype of systemic extranodal non-Hodgkin diffuse large B-cell lymphoma (DLBCL). We report a rare case of IVLBCL who showed diffuse 18F-fluorodeoxyglucose (FDG) uptake in the lung in FDG-positron emission tomography/computed tomography (PET/CT) without respiratory symptoms or chest CT abnormalities. Serum biochemical studies...
متن کاملIntravascular large B-cell lymphoma: report of three cases and analysis of the mTOR pathway.
Intravascular large B-cell lymphoma (IVLBCL) is a rare, aggressive and often fatal non-Hodgkin lymphoma characterized by preferential growth of malignant B-cells within the lumina of small vessels. Rituximab plus anthracycline-based chemotherapy is the current standard regimen for IVLBCL, however it has minimal efficacy in relapsed or refractory diseases. Recent clinical trials have shown a sig...
متن کاملHISTIOCYTE-RICH B-CELL LYMPHOMA: A CASE REPORT OF A RARE VARIANT OF DIFFUSE LARGE B-CELL LYMPHOMA
The authors describe a case of histiocyte-rich B-cell lymphoma (HR-BCL), a variant of diffuse large B-cell lymphoma, in a 51-year-old man. The patient presented with large axillary lymphadenopathy. Histopathologic and immunohistochemical examination of lymph node biopsy revealed diffuse effacement of the lymph node architecture by reactive histiocytes and neoplastic CD20 positive B cells. ...
متن کاملPrimary cutaneous large B cell lymphoma, leg type: A case report and review of the literature
Primary cutaneous large B-cell lymphoma leg type is a rare andaggressive neoplasm as defined by the recently updated WorldHealth Organization - European Organization for Research andTreatment of Cancer. We report a case of an 80-year-old manwith multiple cutaneous lesions. Here, we review the availableliterature and summarize clinical features and management ofthis type of cutaneous B-cell lymp...
متن کاملDevelopment of DOTA-Rituximab kit formulation to be labeled with 90Y for radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...
متن کامل